PANBELA THERAPEUTICS INC (PBLA)

US69833W4042 - Common Stock

1.11  -0.12 (-9.76%)

After market: 1.04 -0.07 (-6.31%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PANBELA THERAPEUTICS INC

NASDAQ:PBLA (3/6/2024, 7:15:57 PM)

After market: 1.04 -0.07 (-6.31%)

1.11

-0.12 (-9.76%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.41M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PBLA Daily chart

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.

Company Info

PANBELA THERAPEUTICS INC

712 Vista Blvd # 305

Waconia MINNESOTA 55387

P: 19524791196

CEO: Jennifer K. Simpson

Employees: 6

Website: https://panbela.com/

PBLA News

News Image2 days ago - InvestorPlacePBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image2 days ago - BusinessInsiderPBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the fourth quarter...

News Image16 days ago - Panbela Therapeutics, Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
News Image16 days ago - Panbela Therapeutics, Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

News Image20 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.

Which stocks are moving after the closing bell on Friday?

News Imagea month ago - Seeking AlphaPanbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) regains compliance with Nasdaq for bid price and publicly held shares, marking a positive development for the clinical stage...

PBLA Twits

Here you can normally see the latest stock twits on PBLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example